Evolution of eligibility criteria for non-transplant randomized controlled trials in adults with acute myeloid leukemia
暂无分享,去创建一个
F. Appelbaum | M. Othus | R. Walter | M. Hunault-Berger | C. Orvain | Gurleen Johal | Gurleen K Johal
[1] L. Churilov,et al. Evolution of eligibility criteria for diffuse large B‐cell lymphoma randomised controlled trials over 30 years , 2021, British journal of haematology.
[2] Ruishan Liu,et al. Evaluating eligibility criteria of oncology trials using real-world data and AI , 2021, Nature.
[3] E. Eisenhauer,et al. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. , 2021, JAMA oncology.
[4] B. Giantonio. Eligibility in Cancer Clinical Research: The Intersection of Discovery, Generalizability, Beneficence, and Justice , 2021, Clinical Cancer Research.
[5] Edward S. Kim,et al. Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO–Friends of Cancer Research Joint Research Statement , 2021, Clinical Cancer Research.
[6] Edward S. Kim,et al. Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations , 2021, Clinical Cancer Research.
[7] J. Cerhan,et al. Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind? , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Sorror,et al. Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility , 2020, Haematologica.
[9] N. Charness,et al. Clinical Trial Generalizability Assessment in the Big Data Era: A Review , 2020, Clinical and translational science.
[10] B. Stevens,et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. , 2019, Blood advances.
[11] J. Unger,et al. Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation , 2019, JAMA oncology.
[12] Dawn L Hershman,et al. Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation , 2019, Journal of the National Cancer Institute.
[13] J. Radich,et al. Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. , 2018, Blood.
[14] Edward S. Kim,et al. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Caroline Schenkel,et al. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Xian-Jin Xie,et al. Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[17] M. Sekeres,et al. The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies , 2017, Leukemia.
[18] E. Estey,et al. A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study , 2017, Leukemia & lymphoma.
[19] F. Vera-Badillo,et al. Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies. , 2016, Cancer treatment reviews.
[20] Keith Humphreys,et al. Representativeness of patients enrolled in influential clinical trials: a comparison of substance dependence with other medical disorders. , 2013, Journal of studies on alcohol and drugs.
[21] Keith Humphreys,et al. Extent and reporting of patient nonenrollment in influential randomized clinical trials, 2002 to 2010. , 2013, JAMA internal medicine.
[22] D. Cescon,et al. Presentation of nonfinal results of randomized controlled trials at major oncology meetings. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] A. Kiss,et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. , 2007, JAMA.
[24] C. Gross,et al. Reporting the Recruitment Process in Clinical Trials: Who Are These Patients and How Did They Get There? , 2002, Annals of Internal Medicine.